You have requested access to member only content.

Beware of category 3: TJC executive offers update on sterile compounding requirements, Part 1

The clinical director of The Joint Commission’s (TJC) Standards Interpretation Group is warning hospitals that one of the greatest risks for noncompliance under revisions to U.S. Pharmacopeia (USP) <797> requirements for compounding sterile medication will be under drugs in the category 3 level.

This is an excerpt from members-only content. Please log in or become a member to access the full content.

Not a member? Let's fix that!

A membership to Accreditation and Quality Compliance Center provides accreditation and safety professionals with a collection of continuously updated tools, best-practice strategies, and compliance tips developed by industry experts. With two membership options, you can customize your access level depending on your education and training needs.

Register to access the free content available on the site or become a member today. Click here for more information.

For questions and support, please call customer service: 800-650-6787.